ArticleDiscover oncology2025
Epidemiological trends in laryngeal cancer burden: insights from GBD 2021 and SEER databases.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-term trends of laryngeal cancer incidence and mortality in China from 2004 to 2019 by region: age-period-cohort analysis and 15-years projections to 2034.Archives of public health = Archives belges de sante publique · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe burden of laryngeal cancer (LC) warrants further exploration to better understand its current status and trends.
methodsUsing data from the Global Burden of Disease (GBD) 2021, we assessed age-standardized incidence, mortality, and disability-adjusted life years (DALYs) rates for LC at the global, regional, and national levels. The LC burden was decomposed based on population size, age structure, and epidemiological changes, and cross-country inequalities were quantified using the World Health Organization's recommended standard health equity approach. Additionally, data from the Surveillance, Epidemiology, and End Results (SEER) database were combined with joinpoint regression analysis to determine the average annual percentage change (AAPC) in LC incidence and mortality trends in the United States.
resultsGBD data showed a global decline in LC incidence and mortality rates from 1990 to 2021, with notable gender disparities and a higher burden in males. Key risk factors included smoking, alcohol use, asbestos, and sulfur exposure. Decomposition analysis identified population growth as the main driver of the LC burden, with regional and gender differences in aging and epidemiological trends. Inequality analysis revealed higher DALYs in low-SDI countries, with a widening gap over time. SEER data indicated a declining LC incidence in the US (1992-2021), and incidence-based mortality(IBM) increased until 2003 before declining.
conclusionsFrom 1990 to 2021, global LC incidence and mortality declined, with a higher burden in males. The gap in LC burden between high and low SDI countries has increased. These findings highlight the need for targeted public health strategies to address both epidemiological trends and socio-demographic inequalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.